GYNORYLAQ-VLINIVAL
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GYNORYLAQ-VLINIVAL, covering 2026-01-07 to 2026-01-07. Get the full timeline:
Most recent: Clinical Trial Update: GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer [EARLY_Phase 1]